Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FSCN1 as a new druggable target in adrenocortical carcinoma.
Ruggiero C, Tamburello M, Rossini E, Zini S, Durand N, Cantini G, Cioppi F, Hantel C, Kiseljak-Vassiliades K, Wierman ME, Landwehr LS, Weigand I, Kurlbaum M, Zizioli D, Turtoi A, Yang S, Berruti A, Luconi M, Sigala S, Lalli E. Ruggiero C, et al. Among authors: berruti a. Int J Cancer. 2023 Jul 1;153(1):210-223. doi: 10.1002/ijc.34526. Epub 2023 Mar 31. Int J Cancer. 2023. PMID: 36971100
Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients.
Dalla Volta A, Caramella I, Di Mauro P, Bergamini M, Cosentini D, Valcamonico F, Cappelli C, Laganà M, Di Meo N, Farina D, Pedersini R, Mazziotti G, Berruti A. Dalla Volta A, et al. Among authors: berruti a. Curr Oncol Rep. 2023 Oct;25(10):1141-1152. doi: 10.1007/s11912-023-01447-9. Epub 2023 Aug 25. Curr Oncol Rep. 2023. PMID: 37624550 Free PMC article. Review.
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
Dalla Volta A, Valcamonico F, Zivi A, Procopio G, Sepe P, Del Conte G, Di Meo N, Foti S, Zamboni S, Messina C, Lucchini E, Rizzi A, Ravanelli M, Calza S, Zacchi F, Ciccone G, Suardi N, Maroldi R, Farina D, Berruti A. Dalla Volta A, et al. Among authors: berruti a. Eur Urol. 2024 May 20:S0302-2838(24)02347-9. doi: 10.1016/j.eururo.2024.05.004. Online ahead of print. Eur Urol. 2024. PMID: 38772788 No abstract available.
Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis.
Pedersini R, Buffoni M, Petrelli F, Ghidini A, di Mauro P, Amoroso V, Parati MC, Laini L, Cosentini D, Schivardi G, Ippolito G, Berruti A, Laganà M. Pedersini R, et al. Among authors: berruti a. Clin Breast Cancer. 2024 Apr 8:S1526-8209(24)00103-4. doi: 10.1016/j.clbc.2024.04.003. Online ahead of print. Clin Breast Cancer. 2024. PMID: 38734491 Free article. Review.
Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma.
Scatolini M, Grisanti S, Tomaiuolo P, Grosso E, Basile V, Cosentini D, Puglisi S, Laganà M, Perotti P, Saba L, Rossini E, Palermo F, Sigala S, Volante M, Berruti A, Terzolo M. Scatolini M, et al. Among authors: berruti a. Eur J Cancer. 2024 Apr 26;205:114088. doi: 10.1016/j.ejca.2024.114088. Online ahead of print. Eur J Cancer. 2024. PMID: 38714106 Free article.
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M, Dalla Volta A, Palumbo C, Zamboni S, Triggiani L, Zamparini M, Laganà M, Rinaudo L, Di Meo N, Caramella I, Bresciani R, Valcamonico F, Borghetti P, Guerini A, Farina D, Antonelli A, Simeone C, Mazziotti G, Berruti A. Bergamini M, et al. Among authors: berruti a. Elife. 2024 Apr 24;13:e92655. doi: 10.7554/eLife.92655. Elife. 2024. PMID: 38656229 Free PMC article. Clinical Trial.
Oncological treatment administration at end of life: a retrospective study.
Gurizzan C, Esposito A, Lorini L, Smussi D, Turla A, Baggi A, Laganà M, Zamparini M, Bianchi S, Volta AD, Grisanti S, Giacomelli L, Berruti A, Bossi P. Gurizzan C, et al. Among authors: berruti a. Future Oncol. 2024 Feb;20(6):329-334. doi: 10.2217/fon-2023-0092. Epub 2024 Feb 29. Future Oncol. 2024. PMID: 38420932
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, Nölting S, de la Fouchardière C, Kienitz T, Deutschbein T, Zovato S, Amar L, Haissaguerre M, Timmers H, Niccoli P, Faggiano A, Angokai M, Lamartina L, Luca F, Cosentini D, Hahner S, Beuschlein F, Attard M, Texier M, Fassnacht M; ENDOCAN-COMETE; ENSAT Networks. Baudin E, et al. Among authors: berruti a. Lancet. 2024 Mar 16;403(10431):1061-1070. doi: 10.1016/S0140-6736(23)02554-0. Epub 2024 Feb 22. Lancet. 2024. PMID: 38402886 Clinical Trial.
520 results